← Leaderboards
John S McMurray
University Of Texas Md Anderson Can Ctr
$2,532,133
Attributed
$2,532,133
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $358.3K · FY2006–09$500K$375K$250K$125K$0
'06
'07
'08
'09
Funding mix
By agency
NIH$2,532,133 · 2
By mechanism
R01$2,385,777 · 1
U19$146,356 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- Mikhail G Kolonin$5,860,228
- Jack Roth$8,028,008
- Zahid H Siddik$6,100,049
- Susan M Fischer$12,916,650
- Ralph Bernard Arlinghaus$3,580,180
Others in their field
Top investigators on “Apoptosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$49,205,802
- Jay A Nelson · Oregon Health & Science University$45,942,124
- John C Reed · University Of Texas Md Anderson Can Ctr$34,437,189
- John A Tainer · Scripps Research Institute$30,637,655
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$28,872,594
- John D Minna · University Of Texas Sw Med Ctr/Dallas$27,317,167
Research focus
ApoptosisTranscription FactorDimerNeoplastic CellPhosphopeptidesPhosphorylationNuclear Magnetic Resonance SpectroscopyChemotherapeutic AgentBreastConformationCellular AssayCancer TherapyCancer TypeAnnexinsBiomaterial Development /PreparationBiological Signal TransductionAffinity ChromatographyBinding (Molecular Function)Cell MembraneCell NucleusCellsCell TypeCell GrowthAntineoplastic Agents
Grant awards (8)
The Development of Stat3 Inhibitors$358,327
R01 · FY2009 · CA · contact PI
The Development of Stat3 Inhibitors$347,886
R01 · FY2008 · CA · contact PI
The Development of Stat3 Inhibitors$335,842
R01 · FY2007 · CA · contact PI
The Development of Stat3 Inhibitors$335,797
R01 · FY2006 · CA · contact PI
The Development of STAT3 Inhibitors.$335,975
R01 · FY2004 · CA
The Development of STAT3 Inhibitors.$335,975
R01 · FY2003 · CA
The Development of STAT3 Inhibitors.$335,975
R01 · FY2002 · CA
SYNTHESIS OF ACTIVE SITE-DIRECTED SRC INHIBITORS$146,356
U19 · FY2000 · CA